Mission GBM

Home
Archive
About
Breakthrough Results from the INDIGO Trial of Vorasidenib in Low Grade Glioma (LGG)
Great news for IDH-mutant LGG patients…and an object lesson in investable theses for brain cancer
 • 
Scott L. Rakestraw, PhD
New
Top
Immuno-Oncology: A Question of Balance
A SARS-CoV-2 infection precipitates a cascading series of immunological adverse events
 • 
Scott L. Rakestraw, PhD
Results That Matter
Team Julie delivers a remarkable outcome based on leading edge clinical science
 • 
Scott L. Rakestraw, PhD
The Central Hypothesis of Immunotherapy and Its Application to Brain Cancer
Rapid advances raise the bar on what can be achieved for patients
 • 
Scott L. Rakestraw, PhD
A Year in the Life
Charting the journey over 365 days of living with GBM
 • 
Scott L. Rakestraw, PhD
Day One Biopharmaceuticals Announces Top Line Data for the FIREFLY-1 Pivotal Phase 2 Trial in Pediatric Low Grade Glioma
Meaningful clinical responses to tovorafenib suggest an important new tool in the Brain Cancer Toolbox
 • 
Scott L. Rakestraw, PhD
Stanford's Innovative Medicines Accelerator and The Invus Group Collaborate to Attack GBM
An important and visionary partnership featuring multiple members of Team Julie
 • 
Scott L. Rakestraw, PhD
Meet the Team: David W. Andrews, MD
Neurosurgeon "par excellence" and Biotech entrepreneur
 • 
Scott L. Rakestraw, PhD
Mission GBM
Mission GBM
Highlighting scientific, clinical and business innovation targeting Glioblastoma Multiforme (GBM) and other Brain Cancers

Mission GBM

AboutArchiveSitemap
© 2023 Scott L. Rakestraw, PhD
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great writing